CannBioRx Life Sciences Corp Cash Flow Conversion Efficiency
CannBioRx Life Sciences Corp cash flow conversion efficiency. Based on the latest financial reports, CannBioRx Life Sciences Corp (ATNFW) has a cash flow conversion efficiency ratio of -0.210x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.13 Million) by net assets ($5.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CannBioRx Life Sciences Corp (2017–2024)
Cash flow conversion efficiency of CannBioRx Life Sciences Corp from 2017 to 2024. This chart illustrates how CannBioRx Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ATNFW share price today for real-time trading data and today's change.
CannBioRx Life Sciences Corp Cash Flow Conversion Ratio Explained
CannBioRx Life Sciences Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CannBioRx Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CannBioRx Life Sciences Corp ranked by their cash flow conversion efficiency. Also see how much is CannBioRx Life Sciences Corp worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mirriad Advertising PLC
LSE:MIRI
|
-1.322x |
|
NEW FRONTIER VENT. INC.
F:S1O
|
0.000x |
|
Ellies
JSE:ELI
|
-0.049x |
|
Tipco Asphalt Public Company Limited
F:TPY1
|
0.122x |
|
PureCycle Technologies Inc
NASDAQ:PCTTW
|
-0.564x |
|
Milton Capital PLC
LSE:MII
|
0.000x |
|
Polyplex (Thailand) Public Company Limited
F:PKW
|
0.014x |
|
Ben Thanh Rubber JSC
VN:BRC
|
N/A |
Annual Cash Flow Conversion Efficiency for CannBioRx Life Sciences Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of CannBioRx Life Sciences Corp from 2017 to 2024. Review ATNFW free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.25 Million | $-1.48 Million | -0.160x | -100.19% |
| 2023-12-31 | $-127.73K | $-10.92 Million | 85.508x | +8098.28% |
| 2022-12-31 | $11.34 Million | $-12.13 Million | -1.069x | -985.73% |
| 2021-12-31 | $39.32 Million | $-3.87 Million | -0.098x | +22.98% |
| 2020-12-31 | $30.29 Million | $-3.87 Million | -0.128x | -48.58% |
| 2019-12-31 | $38.57 Million | $-3.32 Million | -0.086x | -1141.34% |
| 2018-12-31 | $113.87 Million | $-789.23K | -0.007x | -57.23% |
| 2017-12-31 | $112.83 Million | $-497.36K | -0.004x | -- |
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more